7/23
08:06 am
arct
Modified Self-Amplifying RNA Provides Opportunities For New Vaccines And Treatments [Forbes]
Low
Report
Modified Self-Amplifying RNA Provides Opportunities For New Vaccines And Treatments [Forbes]
7/18
07:35 pm
arct
Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 5, 2024 [Yahoo! Finance]
Low
Report
Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 5, 2024 [Yahoo! Finance]
7/18
07:30 pm
arct
Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 5, 2024
Low
Report
Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 5, 2024
7/2
08:00 am
arct
Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $60.00 price target on the stock.
Medium
Report
Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $60.00 price target on the stock.
7/1
04:09 pm
arct
Arcturus Therapeutics Provides Updates for Ornithine Transcarbamylase (OTC) Deficiency and Cystic Fibrosis (CF) Programs [Yahoo! Finance]
Medium
Report
Arcturus Therapeutics Provides Updates for Ornithine Transcarbamylase (OTC) Deficiency and Cystic Fibrosis (CF) Programs [Yahoo! Finance]
7/1
04:01 pm
arct
Arcturus Therapeutics Provides Updates for Ornithine Transcarbamylase (OTC) Deficiency and Cystic Fibrosis (CF) Programs
Medium
Report
Arcturus Therapeutics Provides Updates for Ornithine Transcarbamylase (OTC) Deficiency and Cystic Fibrosis (CF) Programs
6/20
08:16 am
arct
Arcturus Therapeutics Appoints Moncef Slaoui, Ph.D., to Board of Directors [Yahoo! Finance]
Low
Report
Arcturus Therapeutics Appoints Moncef Slaoui, Ph.D., to Board of Directors [Yahoo! Finance]
6/20
08:00 am
arct
Arcturus Therapeutics Appoints Moncef Slaoui, Ph.D., to Board of Directors
Low
Report
Arcturus Therapeutics Appoints Moncef Slaoui, Ph.D., to Board of Directors
6/7
10:42 am
arct
Arcturus Therapeutics Presents New Clinical Data at 47th Annual European Cystic Fibrosis Conference [Yahoo! Finance]
High
Report
Arcturus Therapeutics Presents New Clinical Data at 47th Annual European Cystic Fibrosis Conference [Yahoo! Finance]
6/7
10:30 am
arct
Arcturus Therapeutics Presents New Clinical Data at 47th Annual European Cystic Fibrosis Conference
High
Report
Arcturus Therapeutics Presents New Clinical Data at 47th Annual European Cystic Fibrosis Conference
5/28
06:53 am
arct
Arcturus Therapeutics Announces Positive Development for Cystic Fibrosis Program [Yahoo! Finance]
High
Report
Arcturus Therapeutics Announces Positive Development for Cystic Fibrosis Program [Yahoo! Finance]
5/28
06:30 am
arct
Arcturus Therapeutics Announces Positive Development for Cystic Fibrosis Program
High
Report
Arcturus Therapeutics Announces Positive Development for Cystic Fibrosis Program
5/23
08:11 am
arct
Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) had its "outperform" rating re-affirmed by analysts at William Blair.
Low
Report
Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) had its "outperform" rating re-affirmed by analysts at William Blair.
5/22
04:45 am
arct
Global Coating Additives Market Trends and Forecasts 2024-2035: Strategic Partnerships are Driving Advancements, Asia Holds the Largest Share, Shift Towards Sustainability [Yahoo! Finance]
High
Report
Global Coating Additives Market Trends and Forecasts 2024-2035: Strategic Partnerships are Driving Advancements, Asia Holds the Largest Share, Shift Towards Sustainability [Yahoo! Finance]
5/20
08:42 am
arct
Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine [Yahoo! Finance]
Low
Report
Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine [Yahoo! Finance]
5/20
08:30 am
arct
Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics’ COVID-19 Vaccine
Low
Report
Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics’ COVID-19 Vaccine
5/20
08:30 am
arct
Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine
Low
Report
Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine
5/15
04:01 pm
arct
Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences
Medium
Report
Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences
5/10
03:43 pm
arct
Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $87.00 to $86.00. They now have a "buy" rating on the stock.
Low
Report
Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $87.00 to $86.00. They now have a "buy" rating on the stock.
5/9
11:26 am
arct
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q1 2024 Earnings Call Transcript [Yahoo! Finance]
Low
Report
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q1 2024 Earnings Call Transcript [Yahoo! Finance]
5/9
06:44 am
arct
Arcturus Therapeutics Holdings First Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]
Medium
Report
Arcturus Therapeutics Holdings First Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]
5/8
04:01 pm
arct
Arcturus Therapeutics Announces First Quarter 2024 Financial Update and Pipeline Progress
Medium
Report
Arcturus Therapeutics Announces First Quarter 2024 Financial Update and Pipeline Progress
4/29
10:19 am
arct
Arcturus Therapeutics Holdings' (NASDAQ:ARCT) investors will be pleased with their impressive 284% return over the last five years [Yahoo! Finance]
Low
Report
Arcturus Therapeutics Holdings' (NASDAQ:ARCT) investors will be pleased with their impressive 284% return over the last five years [Yahoo! Finance]